A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 339
- 试验地点
- 105
- 主要终点
- Overall survival
研究概览
简要总结
The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy with sunitinib.
Secondary objectives include a subgroup analysis of overall survival in patients defined by a certain biomarker signature, the investigation of progression-free survival, best tumor response, safety, and immunological parameters.
详细描述
This is a multicenter, open-label, randomized phase III study to investigate whether therapeutic vaccination with IMA901, a mult-peptide cancer vaccine (TUMAP), can prolong overall survival in patients with metastatic and/or locally advanced RCC when added to standard first-line therapy with sunitinib (primary endpoint).
Secondary endpoints include a subgroup analysis of overall survival in patients who are positive for a prospectively defined primary biomarker signature (identified as being predictive for improved clinical outcome in IMA901-vaccinated patients in the previous phase II study), progression-free survival (PFS), best overall response, cellular immunomonitoring in a subset of patients, and safety. Safety analysis will be based on adverse events (AEs), physical examinations, vital signs, hematology, clinical chemistry, urinalysis and ECG changes.
Further endpoints include subgroup analyses of overall survival in patients who are positive for further prospectively defined biomarkers (identified in the previous phase II study), and exploratory screening of new biomarkers (to be investigated in patients' blood and paraffin sections from tumor tissue) to predict better clinical outcome as response to vaccination with IMA901. Biomarker sets will not be used for patient selection in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged at least 18 years.
- •HLA type: HLA-A*02-positive
- •Metastatic and/or locally advanced RCC with clear cell histology (histological confirmation by local pathologist required). NOTE: prior nephrectomy is NOT required.
- •Measurable and/or non-measurable tumor lesions as per RECIST 1.1
- •Patients who are candidates for a first-line therapy with sunitinib.
- •Favorable or intermediate risk according to the 6-score risk criteria in patients treated with VEGF-targeted agents according to Heng [Heng et al. 2009]. The patient has a favorable risk if none, or intermediate risk if one or two of the following criteria apply (if three or more criteria apply the patient is not eligible):
- •Hemoglobin < LLN,
- •Serum corrected calcium > ULN,
- •Karnofsky performance status < 80%,
- •Time from initial diagnosis to initiation of therapy < 1 year,
- •Absolute neutrophil count > ULN,
- •Platelets > ULN.
- •Able to understand the nature of the study and give written informed consent.
- •Willingness and ability to comply with the study protocol for the duration of the study.
- •Female patients who are post menopausal (no menstrual period for a minimum of 1 year), or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or practice a medically acceptable method of birth control.
- •Male patients willing to use contraception (upon study entry and during the course of the study or have undergone vasectomy.
排除标准
- •Prior systemic therapy for metastatic disease. (Note: prior adjuvant treatment for non-metastatic disease is allowed, however adjuvant therapy must have been stopped ≥ 1 year before Visit C).
- •History of or current brain metastases.
- •Abnormal ≥ CTC Grade 3 laboratory values for hematology (Hb, WBC, neutrophils, lymphocytes, platelets), liver (serum bilirubin, ALAT or ASAT) and renal function (serum creatinine).
- •Metastatic second malignancy.
- •Localized second malignancy expected to influence the patient's life span.
- •Patients with a history or evidence of systemic autoimmune disease, e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematodes (SLE), scleroderma, Sjögren's syndrome, Wegener's granulomatosis, Guillain-Barre syndrome.
- •Known active hepatitis B or C infection.
- •Known HIV infection.
- •Active infections requiring oral or intravenous antibiotics.
- •Any other known infection with a biological agent that can cause a severe disease and poses a severe danger to lab personnel working on patients' blood or tissue.
- •Received study drug within any clinical study (including approved and experimental drugs) within 4 weeks before sunitinib start.
- •Serious intercurrent illness, which according to the investigator, poses an undue risk for the patient when participating in the trial, including, but not limited to, any of the following:
- •Clinically significant cardiovascular disease (e.g., uncontrolled hypertension; clinically significant cardiac arrhythmia, clinically significant QT-prolongation),
- •New York Heart Association class III-IV congestive heart failure,
- •Symptomatic peripheral vascular disease,
- •Severe pulmonary dysfunction,
- •Psychiatric illness or social situation that would preclude study compliance.
- •Less than 12 months since any of the following:
- •Myocardial infarction,
- •Severe or unstable angina,
- •Coronary or peripheral artery bypass graft,
- •Cerebrovascular event incl. transient ischemic attack,
- •Pulmonary embolism / deep vein thrombosis (DVT).
- •Pregnancy or breastfeeding.
- •Any condition which in the judgment of the investigator would place the patient at undue risk or interfere with the results of the study.
研究组 & 干预措施
Sunitinib
Sunitib as Standard therapy per Label.
干预措施: Sunitinib (Drug)
IMA901 plus GM-CSF added to sunitinib after single dose of cy
After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant after a single dose of cyclophosphamide will be applied for a period of 4 months while continuing treatment with sunitinib
干预措施: Sunitinib (Drug)
IMA901 plus GM-CSF added to sunitinib after single dose of cy
After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant after a single dose of cyclophosphamide will be applied for a period of 4 months while continuing treatment with sunitinib
干预措施: GM-CSF (Biological)
IMA901 plus GM-CSF added to sunitinib after single dose of cy
After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant after a single dose of cyclophosphamide will be applied for a period of 4 months while continuing treatment with sunitinib
干预措施: Cyclophosphamide (Drug)
IMA901 plus GM-CSF added to sunitinib after single dose of cy
After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant after a single dose of cyclophosphamide will be applied for a period of 4 months while continuing treatment with sunitinib
干预措施: IMA901 (Drug)
结局指标
主要结局
Overall survival
时间窗: 2015 (estimated)
次要结局
- Overall survival in biomarker-defined subgroup(2015 (estimated))
- Best tumor response(2014 (estimated))
- Progression-free survival(2014 (estimated))
- Safety and tolerability(continuously)
- Cellular immunomonitoring(2014 (estimated))